Ontology highlight
ABSTRACT:
SUBMITTER: Shimose S
PROVIDER: S-EPMC11228928 | biostudies-literature | 2024 Aug
REPOSITORIES: biostudies-literature
Shimose Shigeo S Saeki Issei I Tomonari Tetsu T Ito Takanori T Tani Joji J Takeuchi Yasuto Y Yoshioka Naoki N Naito Takehito T Takeuchi Mamiko M Kakizaki Satoru S Hatanaka Takeshi T Sasaki Kyo K Yasunaka Tetsuya T Sakata Masahiro M Iwamoto Hideki H Itano Satoshi S Shirono Tomotake T Tanabe Norikazu N Yamamoto Takafumi T Naganuma Atsushi A Nishina Soji S Otsuka Motoyuki M Kawashima Hiroki H Takayama Tetsuji T Takami Taro T Kawaguchi Takumi T
Oncology letters 20240625 2
Although durvalumab plus tremelimumab (Dur/Tre) has been approved as first-line therapy for patients with unresectable hepatocellular carcinoma (u-HCC), its outcomes in real-world clinical practice are unclear. The present study aimed to evaluate the efficacy and safety of Dur/Tre treatment. This multicenter study was conducted between March 2023 and January 2024, and included 120 patients with u-HCC treated with Dur/Tre. Among the patients, 44 had no history of systemic treatment. Progression-f ...[more]